Theravance Biopharma (TBPH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Theravance Biopharma

NasdaqGM•Healthcare•Biotechnology

$17.02-0.04(<0.01%)Pre-market

Market Cap

$879.37M

P/E

16.3x

P/S

8.4x

P/B

3.0x

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Growth (22/25); weakest: Cash & Earnings Quality (3/25).

Profitability17/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality3/25

Strengths

Growing revenueHigh ROERising earningsInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 16.3x5y range 0.7x – 42.5x

Currently above its 9-quarter median.

P/S · 8.4x5y range 6.3x – 14.8x

Currently near its 20-quarter median.

P/B · 3.0x5y range 1.6x – 3.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $879.37M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $104.31M
Q. Revenue: $20.73M
TTM EBITDA: $-2.78M
TTM Op. Income: $-4.20M
Q. Op. Income: $-8.28M
TTM Net Income: $53.81M
Q. Net Income: $-5.90M
EPS: $-0.11
Shares Out.: $51.67M

$104.31M in TTM revenue grew 35.1% YoY, reaching $20.73M last quarter. TTM EBITDA of $-2.78M and TTM operating income of $-4.20M show growth is flowing through to the bottom line. TTM net income of $53.81M means revenue is converting into profit. Over the past year, TTM revenue is up 35% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -38.2%
Op. Margin: -39.9%
Net Margin: -28.5%

Op. margin of -39.9% is down 29.5% YoY — costs are rising relative to revenue. Net margin at -28.5% Over the past year, operating margin is down 284% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 16.3x
P/S Ratio: 8.4x
P/B Ratio: 3.0x

At 16.3x P/E, the stock trades within typical market levels. P/S of 8.4x and P/B of 3.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 62% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $469.77M
Cash: $219.77M
Long-Term Debt: N/A
Book Value: $289.70M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-6.96M
TTM Free Cash Flow: $53.73M
FCF Margin: 51.5%
FCF / Net Income: 1.0

TTM FCF of $53.73M on $-6.96M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 78% — a weakening trend.